Biologics
-
FDA Approves Biosimilar for Omalizumab (Xolair®)
The FDA’s approval of a biosimilar for omalizumab brings new treatment options for patients. Discover the implications and what it means for you.
All About
Biologics
Biologic drugs are developed from cells of living organisms such as humans, animals or microorganisms. The medications target specific cells, proteins and pathways that cause inflammation in the body.
